Dr. Preetesh Jain, MD

Dr. Jain practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Jain's NPI, 1578981221, was assigned on March 31, 2014. Dr. Jain graduated from Government Medical College Vijayanagar in 2002. Dr. Jain holds Texas license R1968.

Dr. Jain's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Jain's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Jain is also affiliated with UT Health San Antonio Multispecialty and Research Hospital. The medical group on file is UT Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jain practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jain's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Jain is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Jain's licenses on file in 10 states: Texas, Florida, Arizona, Tennessee, Washington, Georgia, Louisiana, Alabama, Mississippi and Oklahoma.

Dmand AI lists acute respiratory failure, congestive heart failure, hypercalcemia, immune deficiency disease, kidney failure and pneumonia and respiratory infection among the conditions Dr. Jain treats.

CMS data shows 961 Medicare services from Dr. Jain across 9 procedure codes in 2024, for 275 Medicare patients. Medicare paid $79,229 for them.

CMS counts 275 Medicare patients who saw Dr. Jain in 2024. The largest group is 65 to 74, with 138 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jain's median patient age at 73, with 34% women.

In 2024, Dr. Jain wrote 636 Medicare Part D claims for 129 patients. 61% of them were for generic drugs. CMS names the drug for 486 of them, across 12 drugs with 11 or more claims each, at $3,320,964 in total drug cost. In 2023, CMS named 152 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jain for performance year 2024, reported as part of a group. Dr. Jain accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jain as offering telehealth.

Dmand AI links 157 papers to Dr. Jain, published from 2011 to 2025. 2016 was the busiest year, with 14. The most frequent topics are Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell and Antineoplastic Combined Chemotherapy Protocols. Dr. Jain has published most often in Am J Hematol. Dr. Jain's most frequent co-authors are Zeev Estrov, MD, Hagop M. Kantarjian, MD and Susan M. O'Brien, MD.

Dmand AI links Dr. Jain to 3 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin and Hematologic Neoplasms. M.D. Anderson Cancer Center sponsors the most, 3.

CMS Open Payments shows 85 general payments to Dr. Jain from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 90% of the total. Eli Lilly and Company paid the most, $49,282.

Dr. Jain graduated from Government Medical College Vijayanagar in 2002.

Dr. Jain is in network with 5 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. POS plans come from the most carriers, 3. Check the plan with the practice before a visit.